Bladder Cancer

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Novel FGFR3 Inhibitor May Be a New Treatment Option for Metastatic Urothelial Carcinoma

Novel FGFR3 Inhibitor May Be a New Treatment Option for Metastatic Urothelial Carcinoma

By

Previous early phase clinical studies have demonstrated that BGJ398 was active and well tolerated in a variety of FGFR-altered cancers.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Active Surveillance After Complete Response to Chemotherapy May Be Effective in Bladder Cancer

Active Surveillance After Complete Response to Chemotherapy May Be Effective in Bladder Cancer

By

Many patients are cured of all disease (pT0) post-chemotherapy and may be able to defer invasive surgery if properly identified.

Postresection intravesical instillation of gemcitabine decreases non-muscle-invasive urothelial cancer recurrence

In this randomized controlled trial, instilling postresection chemotherapy, specifically gemcitabine, was found to decrease tumor recurrence in non-muscle-invasive urothelial cancer when compared to saline treatment as a placebo.

Bladder Cancer, UTUC More Common in Kidney Transplant Recipients

Bladder Cancer, UTUC More Common in Kidney Transplant Recipients

By

A study found that bladder cancer and UTUC occurred in 122.22 and 113.97 per 100,000 persons per year, respectively, among kidney transplant recipients.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Neoadjuvant Dose-Dense Gemcitabine, Cisplatin May Be an Ideal Regimen in Bladder Cancer

Neoadjuvant Dose-Dense Gemcitabine, Cisplatin May Be an Ideal Regimen in Bladder Cancer

By

Various aspects of optimal treatment, such as optimal dose, drug combination, number of cycles, and duration of therapy have yet to be clearly defined for patients with bladder cancer.

The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

By

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

By

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

Pembrolizumab Before Radical Cystectomy: Safe and Effective in Urothelial Carcinoma

Pembrolizumab Before Radical Cystectomy: Safe and Effective in Urothelial Carcinoma

By

One instance of grade 3 alanine aminotransferase elevation and 5 instances of reversible immune-related adverse events were observed.

Tumor Cell Lysate Vaccine Shows Promise

Tumor Cell Lysate Vaccine Shows Promise

By

Antigen-specific T cells increased in frequency in vaccinated mice.

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

By

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

By

Phase 1 trials should be considered therapeutic options for some patients.

Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

By

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

Can A Consortium of Hospitals Help To Reduce Drug Prices?

Can A Consortium of Hospitals Help To Reduce Drug Prices?

By

To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.

Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma

Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma

By

Erdafitinib — an oral pan-fibroblast growth factor receptor tyrosine kinase inhibitor (FGFR-TKI) — is the first targeted therapy for urothelial cancer.

Larotrectinib: Promising for All TRK-Positive Tumors

Larotrectinib: Promising for All TRK-Positive Tumors

By

Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.

Liquid Biopsy May Accurately Detect Genomic Mutations in Urothelial Carcinoma

Liquid Biopsy May Accurately Detect Genomic Mutations in Urothelial Carcinoma

By

Because tissue biopsy is not always possible in patients with mUC, identifying the optimal targeted therapy or clinical trial can be challenging.

Diagnosing Medicine's Intractable Gender Pay Gap

Diagnosing Medicine's Intractable Gender Pay Gap

By

The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.

Managing Adverse Events in the Era of Immunotherapy

Managing Adverse Events in the Era of Immunotherapy

By

The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.

Muscle-Invasive Bladder Cancer: The Evolving Treatment Landscape

Muscle-Invasive Bladder Cancer: The Evolving Treatment Landscape

By

Patients diagnosed with MIBC are at a significant risk for death — which has not greatly improved in the last few decades.

Ramucirumab Plus Docetaxel May Improve QoL in Urothelial Carcinoma

Ramucirumab Plus Docetaxel May Improve QoL in Urothelial Carcinoma

By

The impact of this treatment on quality of life was not previously reported.

5-FU/Cisplatin, Gemcitabine May Be Effective Options for Invasive Bladder Cancer

5-FU/Cisplatin, Gemcitabine May Be Effective Options for Invasive Bladder Cancer

By

This study was designed to evaluate the efficacy of each treatment using 3-year distant metastasis-free survival as a primary outcome.

Pembrolizumab Improves OS, ORR After 2 Years vs Chemotherapy in Urothelial Cancer

Pembrolizumab Improves OS, ORR After 2 Years vs Chemotherapy in Urothelial Cancer

By

Of 542 enrolled patients, 270 were randomly assigned to pembrolizumab and 272 were assigned to chemotherapy. All patients progressed after platinum therapy.

Adjuvant Chemotherapy May Be New Standard of Care for Upper Tract Urothelial Cancer

Adjuvant Chemotherapy May Be New Standard of Care for Upper Tract Urothelial Cancer

By

The median follow-up was 17.6 months at time of interim analysis.

Nivolumab Monotherapy May Yield 8% Complete Response Rate in Urothelial Carcinoma

Nivolumab Monotherapy May Yield 8% Complete Response Rate in Urothelial Carcinoma

By

Seventy-eight patients with metastatic urothelial carcinoma received intravenous nivolumab until disease progression or discontinuation.

Healthful Lifestyles and Cancer: Much More Than A Single Behavior

Healthful Lifestyles and Cancer: Much More Than A Single Behavior

By

A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.

Cancer Immunosurveillance Comes of Age

Cancer Immunosurveillance Comes of Age

By

As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.

Does Immune Checkpoint Inhibition Have A Dark Side?

Does Immune Checkpoint Inhibition Have A Dark Side?

By

Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs